This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (361)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Choroidal Neovascularization  • Macular Degeneration  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic

One-Year Results of 2 Randomized Clinical Trials—TAP Report 1

Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group

Arch Ophthalmol. 1999;117:1329-1345.

Objective  To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, Ga) can safely reduce the risk of vision loss in patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).

Design  Two multicenter, double-masked, placebo-controlled, randomized clinical trials.

Setting  Twenty-two ophthalmology practices in Europe and North America.

Participants  Patients with subfoveal CNV lesions caused by AMD measuring 5400 µm or less in greatest linear dimension with evidence of classic CNV and best-corrected visual acuity of approximately 20/40 to 20/200.

Methods  Six hundred nine patients were randomly assigned (2:1) to verteporfin (6 mg per square meter of body surface area) or placebo (5% dextrose in water) administered via intravenous infusion of 30 mL over 10 minutes. Fifteen minutes after the start of the infusion, a laser light at 689 nm delivered 50 J/cm² at an intensity of 600 mW/cm² over 83 seconds using a spot size with a diameter 1000 µm larger than the greatest linear dimension of the CNV lesion. At follow-up examinations every 3 months, retreatment with the same regimen was applied if angiography showed fluorescein leakage. The primary outcome was the proportion of eyes with fewer than 15 letters lost (approximately <3 lines of loss), adhering to an intent-to-treat analysis.

Results  In each group, 94% of patients completed the month 12 examination. Visual acuity, contrast sensitivity, and fluorescein angiographic outcomes were better in the verteporfin-treated eyes than in the placebo-treated eyes at every follow-up examination through the month 12 examination. At the month-12 examination, 246 (61%) of 402 eyes assigned to verteporfin compared with 96 (46%) of 207 eyes assigned to placebo had lost fewer than 15 letters of visual acuity from baseline (P<.001). In subgroup analyses, the visual acuity benefit (<15 letters lost) of verteporfin therapy was clearly demonstrated (67% vs 39%; P<.001) when the area of classic CNV occupied 50% or more of the area of the entire lesion (termed predominantly classic CNV lesions), especially when there was no occult CNV. No statistically significant differences in visual acuity were noted when the area of classic CNV was more than 0% but less than 50% of the area of the entire lesion. Few ocular or other systemic adverse events were associated with verteporfin treatment, compared with placebo, including transient visual disturbances (18% vs 12%), injection-site adverse events (13% vs 3%), transient photosensitivity reactions (3% vs 0%), and infusion-related low back pain (2% vs 0%).

Conclusions  Since verteporfin therapy of subfoveal CNV from AMD can safely reduce the risk of vision loss, we recommend verteporfin therapy for treatment of patients with predominantly classic CNV from AMD.

A complete list of the participants in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group appears below.

RELATED ARTICLES

Photodynamic Therapy With Verteporfin Is Effective for Selected Patients With Neovascular Age-related Macular Degeneration
Stuart L. Fine
Arch Ophthalmol. 1999;117(10):1400-1402.
EXTRACT | FULL TEXT  

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 1999;117(10):1452.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Coagulation Gene Predictors of Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration
Parmeggiani et al.
IOVS 2008;49:3100-3106.
ABSTRACT | FULL TEXT  

Optical coherence tomography: limits of the retinal-mapping program in age-related macular degeneration
Krebs et al.
Br. J. Ophthalmol. 2008;92:933-935.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration
Jager et al.
NEJM 2008;358:2606-2617.
FULL TEXT  

Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization
Tatar et al.
Arch Ophthalmol 2008;126:782-790.
ABSTRACT | FULL TEXT  

The effects of photodynamic therapy on conjunctival in situ squamous cell carcinoma - a review of the histopathology
Sears et al.
Br. J. Ophthalmol. 2008;92:716-717.
FULL TEXT  

Evaluation of the New Photosensitizer Stakel (WST-11) for Photodynamic Choroidal Vessel Occlusion in Rabbit and Rat Eyes
Berdugo et al.
IOVS 2008;49:1633-1644.
ABSTRACT | FULL TEXT  

Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study
Kriechbaum et al.
Br. J. Ophthalmol. 2008;92:518-522.
ABSTRACT | FULL TEXT  

Photodynamic Therapy for Corneal Neovascularization Using Polymeric Micelles Encapsulating Dendrimer Porphyrins
Sugisaki et al.
IOVS 2008;49:894-899.
ABSTRACT | FULL TEXT  

Subretinal Bevacizumab Detection after Intravitreous Injection in Rabbits
Dib et al.
IOVS 2008;49:1097-1100.
ABSTRACT | FULL TEXT  

Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium
Csaky et al.
IOVS 2008;49:479-489.
FULL TEXT  

Experimental selective choriocapillaris photothrombosis using a modified indocyanine green formulation
Cardillo et al.
Br. J. Ophthalmol. 2008;92:276-280.
ABSTRACT | FULL TEXT  

Improved Vision-Related Function After Ranibizumab Treatment of Neovascular Age-Related Macular Degeneration: Results of a Randomized Clinical Trial
Chang et al.
Arch Ophthalmol 2007;125:1460-1469.
ABSTRACT | FULL TEXT  

Photodynamic Therapy Induces Caspase-Dependent Apoptosis in Rat CNV Model
Matsubara et al.
IOVS 2007;48:4741-4747.
ABSTRACT | FULL TEXT  

Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2
Mochimaru et al.
IOVS 2007;48:4795-4801.
ABSTRACT | FULL TEXT  

Incident Choroidal Neovascularization in Fellow Eyes of Patients With Unilateral Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: SST Report No. 20 From the Submacular Surgery Trials Research Group
Submacular Surgery Trials Research Group
Arch Ophthalmol 2007;125:1323-1330.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Bashshur et al.
Arch Ophthalmol 2007;125:1357-1361.
ABSTRACT | FULL TEXT  

Long-term Follow-up of Macular Translocation With 360{degrees} Retinotomy for Exudative Age-Related Macular Degeneration
Aisenbrey et al.
Arch Ophthalmol 2007;125:1367-1372.
ABSTRACT | FULL TEXT  

The 100 Most Frequently Cited Articles in Ophthalmology Journals
Ohba et al.
Arch Ophthalmol 2007;125:952-960.
ABSTRACT | FULL TEXT  

25-gauge vs 20-gauge system for pars plana vitrectomy: a prospective randomised clinical trial
Kellner et al.
Br. J. Ophthalmol. 2007;91:945-948.
ABSTRACT | FULL TEXT  

Photodynamic therapy in the anti-VEGF era
Fine
Br. J. Ophthalmol. 2007;91:707-708.
FULL TEXT  

Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration
Potter and Szabo
Br. J. Ophthalmol. 2007;91:753-756.
ABSTRACT | FULL TEXT  

Correlation between Focal Macular Electroretinograms and Angiographic Findings after Photodynamic Therapy
Ishikawa et al.
IOVS 2007;48:2254-2259.
ABSTRACT | FULL TEXT  

Age-related macular degeneration and recent developments: new hope for old eyes?
Morris et al.
Postgrad. Med. J. 2007;83:301-307.
ABSTRACT | FULL TEXT  

Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation
Giovannini et al.
Br. J. Ophthalmol. 2007;91:620-623.
ABSTRACT | FULL TEXT  

Autologous retinal pigment epithelium-choroid sheet transplantation in age related macular degeneration: morphological and functional results
Treumer et al.
Br. J. Ophthalmol. 2007;91:349-353.
ABSTRACT | FULL TEXT  

Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes
Tatar et al.
Br. J. Ophthalmol. 2007;91:166-173.
ABSTRACT | FULL TEXT  

New treatments for age-related macular degeneration
Imrie and Bailey
Age Ageing 2007;36:8-10.
FULL TEXT  

Quantitative Fluorescein Angiographic Analysis of Choroidal Neovascular Membranes: Validation and Correlation with Visual Function
Chakravarthy et al.
IOVS 2007;48:349-354.
ABSTRACT | FULL TEXT  

Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro
Obata et al.
Br. J. Ophthalmol. 2007;91:100-104.
ABSTRACT | FULL TEXT  

Evaluation of the New Photosensitizer Tookad (WST09) for Photodynamic Vessel Occlusion of the Choroidal Tissue in Rabbits
Framme et al.
IOVS 2006;47:5437-5446.
ABSTRACT | FULL TEXT  

Dynamic and Quantitative Analysis of Choroidal Neovascularization by Fluorescein Angiography
Shah et al.
IOVS 2006;47:5460-5468.
ABSTRACT | FULL TEXT  

Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy
Imai et al.
Br. J. Ophthalmol. 2006;90:1524-1530.
ABSTRACT | FULL TEXT  

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: Year 1 Results of the FOCUS Study.
Heier et al.
Arch Ophthalmol 2006;124:1532-1542.
ABSTRACT | FULL TEXT  

Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld et al.
NEJM 2006;355:1419-1431.
ABSTRACT | FULL TEXT  

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown et al.
NEJM 2006;355:1432-1444.
ABSTRACT | FULL TEXT  

Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model.
Korobelnik et al.
IOVS 2006;47:4270-4276.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study.
Costa et al.
IOVS 2006;47:4569-4578.
ABSTRACT | FULL TEXT  

Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration
Kozak et al.
Br. J. Ophthalmol. 2006;90:1152-1156.
ABSTRACT | FULL TEXT  

Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes
Petermeier et al.
Br. J. Ophthalmol. 2006;90:1034-1039.
ABSTRACT | FULL TEXT  

Predictors of Visual Outcome and Choroidal Neovascular Membrane Formation After Traumatic Choroidal Rupture
Ament et al.
Arch Ophthalmol 2006;124:957-966.
ABSTRACT | FULL TEXT  

Pegaptanib: A Novel Approach to Ocular Neovascularization
Chapman and Beckey
The Annals of Pharmacotherapy 2006;40:1322-1326.
ABSTRACT | FULL TEXT  

The proteome of central and peripheral retina with progression of age-related macular degeneration.
Ethen et al.
IOVS 2006;47:2280-2290.
ABSTRACT | FULL TEXT  

Lesion morphology in age-related macular degeneration and its therapeutic significance.
Beaumont and Kang
Arch Ophthalmol 2006;124:807-812.
ABSTRACT | FULL TEXT  

Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.
Tatar et al.
Arch Ophthalmol 2006;124:815-823.
ABSTRACT | FULL TEXT  

Micropulse and continuous wave diode retinal photocoagulation: visible and subvisible lesion parameters
Desmettre et al.
Br. J. Ophthalmol. 2006;90:709-712.
ABSTRACT | FULL TEXT  

A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT  

Occult With No Classic Subfoveal Choroidal Neovascular Lesions in Age-Related Macular Degeneration: Clinically Relevant Natural History Information in Larger Lesions With Good Vision From the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
Writing Committee for the VIP Study Group
Arch Ophthalmol 2006;124:660-664.
ABSTRACT | FULL TEXT  

Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation.
Freund et al.
Arch Ophthalmol 2006;124:487-492.
ABSTRACT | FULL TEXT  

Correlation of optical coherence tomography and fundus fluorescein angiography following photodynamic therapy for choroidal neovascular membranes.
Van de Moere et al.
Br. J. Ophthalmol. 2006;90:304-306.
ABSTRACT | FULL TEXT  

Iris Pigment Epithelial Translocation in the Treatment of Exudative Macular Degeneration: A 3-Year Follow-up.
Aisenbrey et al.
Arch Ophthalmol 2006;124:183-188.
ABSTRACT | FULL TEXT  

Which treatment is best for which AMD patient?
Kroll and Meyer
Br. J. Ophthalmol. 2006;90:128-130.
FULL TEXT  

Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial
Stolba et al.
Br. J. Ophthalmol. 2006;90:158-161.
ABSTRACT | FULL TEXT  

Ultrahigh resolution optical coherence tomography in non-exudative age related macular degeneration
Pieroni et al.
Br. J. Ophthalmol. 2006;90:191-197.
ABSTRACT | FULL TEXT  

Influence of Treatment Parameters on Selectivity of Verteporfin Therapy
Michels et al.
IOVS 2006;47:371-376.
ABSTRACT | FULL TEXT  

Ocular Changes after Photodynamic Therapy
Tzekov et al.
IOVS 2006;47:377-385.
ABSTRACT | FULL TEXT  

Risk Factors for Age-Related Macular Degeneration: Findings from the Andhra Pradesh Eye Disease Study in South India
Krishnaiah et al.
IOVS 2005;46:4442-4449.
ABSTRACT | FULL TEXT  

Treatment of Retinal Angiomatous Proliferation in Age-Related Macular Degeneration: A Series of 104 Cases of Retinal Angiomatous Proliferation
Bottoni et al.
Arch Ophthalmol 2005;123:1644-1650.
ABSTRACT | FULL TEXT  

Retinal Anastomosis to Choroidal Neovascularization: A Bum Rap for a Difficult Disease
Bressler
Arch Ophthalmol 2005;123:1741-1743.
FULL TEXT  

Choroidal neovascularisation in pathological myopia: an update in management
Chan et al.
Br. J. Ophthalmol. 2005;89:1522-1528.
ABSTRACT | FULL TEXT  

Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation
Hogan et al.
Br. J. Ophthalmol. 2005;89:1109-1111.
ABSTRACT | FULL TEXT  

Optical coherence tomography guided retreatment of photodynamic therapy
Krebs et al.
Br. J. Ophthalmol. 2005;89:1184-1187.
ABSTRACT | FULL TEXT  

Choroidal Infarction Following Photodynamic Therapy With Verteporfin
Klais et al.
Arch Ophthalmol 2005;123:1149-1153.
FULL TEXT  

Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes
Sandhu and Talks
Br. J. Ophthalmol. 2005;89:967-970.
ABSTRACT | FULL TEXT  

Macular Function after PDT in Myopic Maculopathy: Psychophysical and Electrophysiological Evaluation
Varano et al.
IOVS 2005;46:1453-1462.
ABSTRACT | FULL TEXT  

Verteporfin Therapy of Subfoveal Minimally Classic Choroidal Neovascularization in Age-Related Macular Degeneration: 2-Year Results of a Randomized Clinical Trial
Visudyne in Minimally Classic Choroidal Neovascula
Arch Ophthalmol 2005;123:448-457.
ABSTRACT | FULL TEXT  

Safety and Efficacy of Intravitreal Injection of Ranibizumab in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization in the Monkey
Husain et al.
Arch Ophthalmol 2005;123:509-516.
ABSTRACT | FULL TEXT  

Inhibitors of Ocular Neovascularization: Promises and Potential Problems
van Wijngaarden et al.
JAMA 2005;293:1509-1513.
FULL TEXT  

Stability of Visual Acuity Measurement in Depression
Rovner and Casten
AJGP 2005;13:255-258.
ABSTRACT | FULL TEXT  

Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration
Arias et al.
Br. J. Ophthalmol. 2005;89:312-315.
ABSTRACT | FULL TEXT  

Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: a cross sectional study
Sahni et al.
Br. J. Ophthalmol. 2005;89:316-320.
ABSTRACT | FULL TEXT  

RPE Damage Thresholds and Mechanisms for Laser Exposure in the Microsecond-to-Millisecond Time Regimen
Schuele et al.
IOVS 2005;46:714-719.
ABSTRACT | FULL TEXT  

Photodynamic therapy for inflammatory choroidal neovascularisation unresponsive to immunosuppression
Leslie et al.
Br. J. Ophthalmol. 2005;89:147-150.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin: Observations on the Introduction of a New Treatment Into Clinical Practice
Schein et al.
Arch Ophthalmol 2005;123:58-63.
ABSTRACT | FULL TEXT  

Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema
Luttrull et al.
Br. J. Ophthalmol. 2005;89:74-80.
ABSTRACT | FULL TEXT  

Pegaptanib for Neovascular Age-Related Macular Degeneration
Gragoudas et al.
NEJM 2004;351:2805-2816.
ABSTRACT | FULL TEXT  

A New Treatment for Ocular Neovascularization
Ferris
NEJM 2004;351:2863-2865.
FULL TEXT  

Inhibition of Choroidal Neovascularization by a Peptide Inhibitor of the Urokinase Plasminogen Activator and Receptor System in a Mouse Model
Das et al.
Arch Ophthalmol 2004;122:1844-1849.
ABSTRACT | FULL TEXT  

Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Jonas et al.
Br. J. Ophthalmol. 2004;88:1557-1562.
ABSTRACT | FULL TEXT  

Outcome of Transplantation of Autologous Retinal Pigment Epithelium in Age-Related Macular Degeneration: A Prospective Trial
Binder et al.
IOVS 2004;45:4151-4160.
ABSTRACT | FULL TEXT  

BDNF Reduces the Retinal Toxicity of Verteporfin Photodynamic Therapy
Paskowitz et al.
IOVS 2004;45:4190-4196.
ABSTRACT | FULL TEXT  

Photodynamic therapy of circumscribed choroidal haemangioma
Singh et al.
Br. J. Ophthalmol. 2004;88:1414-1418.
ABSTRACT | FULL TEXT  

CAI Is a Potent Inhibitor of Neovascularization and Imparts Neuroprotection in a Mouse Model of Ischemic Retinopathy
Franklin et al.
IOVS 2004;45:3756-3766.
ABSTRACT | FULL TEXT  

Acute Severe Vision Decrease Immediately After Photodynamic Therapy
Beaumont et al.
Arch Ophthalmol 2004;122:1546-1547.
FULL TEXT  

A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration
Armbrecht et al.
Br. J. Ophthalmol. 2004;88:1270-1273.
ABSTRACT | FULL TEXT  

Colour vision testing as an aid to diagnosis and management of age related maculopathy
Arden and Wolf
Br. J. Ophthalmol. 2004;88:1180-1185.
ABSTRACT | FULL TEXT  

Time trends in personnel certification and turnover in the Collaborative Ocular Melanoma Study
Mobley et al.
Clin Trials 2004;1:377-386.
ABSTRACT  

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration
Hopley et al.
Br. J. Ophthalmol. 2004;88:982-987.
ABSTRACT | FULL TEXT  

Indocyanine green mediated photothrombosis for the management of predominantly classic choroidal neovascularisation caused by age related macular degeneration
Farah et al.
Br. J. Ophthalmol. 2004;88:1055-1059.
ABSTRACT | FULL TEXT  

Selective Photodynamic Therapy by Targeted Verteporfin Delivery to Experimental Choroidal Neovascularization Mediated by a Homing Peptide to Vascular Endothelial Growth Factor Receptor-2
Renno et al.
Arch Ophthalmol 2004;122:1002-1011.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Results of an Effectiveness Study
Sharma et al.
Arch Ophthalmol 2004;122:853-856.
ABSTRACT | FULL TEXT  

Application of femtosecond ultrashort pulse laser to photodynamic therapy mediated by indocyanine green
Sawa et al.
Br. J. Ophthalmol. 2004;88:826-831.
ABSTRACT | FULL TEXT  

Morphometric Analysis of Angiograms of Exudative Lesions in Age-Related Macular Degeneration
Ali et al.
Arch Ophthalmol 2004;122:710-715.
ABSTRACT | FULL TEXT  

Treatment of age-related macular degeneration
Browning et al.
JRSM 2004;97:166-169.
FULL TEXT  

Photodynamic Therapy for Occult Choroidal Neovascularization With Pigment Epithelium Detachment in Age-Related Macular Degeneration
Axer-Siegel et al.
Arch Ophthalmol 2004;122:453-459.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration: Treating the Whole Patient
Tasman and Rovner
Arch Ophthalmol 2004;122:648-649.
FULL TEXT  

Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants
Hopley et al.
Br. J. Ophthalmol. 2004;88:450-454.
ABSTRACT | FULL TEXT  

Natural History of Minimally Classic Subfoveal Choroidal Neovascular Lesions in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation: Outcomes Potentially Relevant to Management--TAP Report No. 6
Bressler et al.
Arch Ophthalmol 2004;122:325-329.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration
Rechtman et al.
Br. J. Ophthalmol. 2004;88:344-347.
ABSTRACT | FULL TEXT  

The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology
The Complications of Age-Related Macular Degenerat
Clin Trials 2004;1:91-107.
ABSTRACT  

Changes in Focal Macular ERGs after Macular Translocation Surgery with 360{degrees} Retinotomy
Terasaki et al.
IOVS 2004;45:567-573.
ABSTRACT | FULL TEXT